查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1519362

2024-2032 年按類型、藥物類別、適應症、劑型、配銷通路和地區分類的眼科藥物市場報告

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球眼科藥物市場規模達450億美元。被診斷患有眼部疾病的人數不斷增加、給藥系統的重大技術進步、有利的政府舉措和資金、老年人口的增加以及患有糖尿病的人數不斷增加，推動了市場的發展。

眼科藥物市場分析：

主要市場促進因素：與眼睛相關的日益嚴重的問題、藥物配方的重大發展以及對技術和藥物研究領域的強勁投資是推動眼科藥物成長的一些主要市場促進因素。

主要市場趨勢：選擇聯合療法的人數不斷增加，產業參與者之間的策略夥伴關係不斷增強，以及越來越重視為以前被認為無法治療的疾病創造治療方法，這些都是眼科藥物市場趨勢。

地理趨勢：北美憑藉強大的醫療基礎設施和不斷增加的糖尿病相關眼部疾病診斷數量而引領市場。該行業的第二大市場是歐洲，因為該地區人口老化加劇以及研發（R&D）活動不斷增加。

競賽格局：AbbVie Inc.、Aerie Pharmaceuticals Inc.、Akorn Inc.、Alcon、Bausch Health Companies Inc.、Bayer AG、F. Hoffmann-La Roche AG、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Regeneron Pharmaceuticals Inc.、Santen Pharmaceutical Co. Ltd. 和Sun Pharmaceutical Industries Ltd 是眼科藥物行業的一些主要參與者。

挑戰與機會：該市場的挑戰包括嚴格的監管環境導致藥物核准延遲以及開發的眼科藥物成本上升。此外，眼科藥物市場近期的機會包括新興市場的潛力，這些市場被認可的醫療保健機會不斷增加。

眼科藥物市場趨勢：

個人眼疾患率上升

全球範圍內日益增加的與眼睛相關的問題極大地增加了眼科藥物的需求。根據資料，白內障、青光眼、老年黃斑部病變（AMD）和糖尿病視網膜病變等疾病正在推動市場發展。根據世界衛生組織 (WHO) 的數據，每年至少有 22 億人有近距視力障礙。該報告還指出，至少有 10 億個視力障礙病例本來可以避免或尚未預防。患有眼部疾病的人數不斷增加，顯著導致對這些治療藥物（例如抗青光眼藥物、抗 VEGF 藥物和抗發炎藥物）的需求增加。這種相關性得到了許多市場研究報告的支持，這些報告描述了有前途的先進治療解決方案並促進了眼科藥物市場的最新開發活動。

藥物輸送系統的重大技術進步

可以認可新技術的藥物輸送系統的創新是創造積極的眼科藥物市場概況的主要因素。微乳液、奈米技術或眼部植入物等新配方的可能性提供了更好的功效、安全性和患者依從性。例如，奈米級的藥物載體可以顯著提高藥物對目標眼組織的生物利用度，從而減少頻繁給藥的需要以及與藥物相關的任何副作用。因此，越來越多的公司正在投資這些技術，以獲得市場競爭優勢。業界新型眼科給藥系統專利數量不斷增加。上述所有研發 (R&D) 投資均以受益於新藥物輸送技術的細分市場的市場成長預測為基礎。這意味著他們有能力顯著破壞目前的眼科治療模式。

有利的政府措施和資金

政府政策是創造積極的眼科藥物市場前景的重要因素。世界各國政府推出了各種措施來改善醫療基礎設施，包括讓有效的眼部護理更容易獲得。例如，許多國家提供了補貼眼科護理中心的開設和發展、投資研究以創造新藥以及傳播有關眼科疾病的資訊的機會。在美國，國家眼科研究所為眼科領域的研究提供大量資金。這推動了這一領域的重大突破，為行業的良好願景開闢了新藥和機會。此外，透過 FDA 的突破性治療指定等途徑加快藥物核准，可提高有遠見的眼科解決方案的市場准入。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球眼科藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 處方藥
    • 市場走向
    • 市場預測
  • 非處方藥物
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依藥物類別

  • 抗青光眼
    • 市場走向
    • 市場預測
  • 抗感染
    • 市場走向
    • 市場預測
  • 抗發炎
    • 市場走向
    • 市場預測
  • 抗過敏
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依跡象

  • 乾眼症
    • 市場走向
    • 市場預測
  • 青光眼
    • 市場走向
    • 市場預測
  • 感染/發炎/過敏
    • 市場走向
    • 市場預測
  • 視網膜疾病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按劑型

  • 液體眼科藥物劑型
    • 市場走向
    • 市場預測
  • 固體眼科藥物劑型
    • 市場走向
    • 市場預測
  • 半固體眼科藥物劑型
    • 市場走向
    • 市場預測
  • 多室給藥系統
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 12 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 15 章：價格分析

第16章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Aerie Pharmaceuticals Inc.
    • Akorn Inc.
    • Alcon
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: SR112024A5287

The global ophthalmic drugs market size reached US$ 45.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 68.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032. The market is propelled by the rising number of individuals diagnosed with eye diseases, significant technological advancements in drug delivery systems, favorable government initiatives and funding, rising geriatric population, and increasing number of individuals suffering with diabetes.

Ophthalmic Drugs Market Analysis:

Major Market Drivers: The rising issues related to eyes, significant developments in drug formulations, and robust investment in technology and pharmaceutical research sectors are some of the major market drivers driving the ophthalmic drugs growth.

Key Market Trends: The rising number of individuals opting for combination therapies, increasing strategic partnerships among industry players, and the rising emphasis on creating treatments for conditions that were considered untreatable previously are some of the ophthalmic drugs market trends.

Geographical Trends: North America leads the market on account of a strong healthcare infrastructure and the increasing amount of diagnosis of diabetes-related eye conditions. The second largest market of the industry is Europe due to its rising aging population and increasing research and development (R&D) activities across the region.

Competitive Landscape: AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd, are among some of the key players in the ophthalmic drugs industry.

Challenges and Opportunities: Challenges of this market include the strict regulatory environments which lead to a delay in drug approvals and rising cost of developed ophthalmic drugs. Moreover, ophthalmic drugs market recent opportunities include the potential of the emerging markets accredited to the rising healthcare access.

Ophthalmic Drugs Market Trends:

Rising Prevalence of Eye Diseases Among Individuals

The increasing eye-related issues worldwide are majorly escalating the ophthalmic drugs demand. As per the data, illnesses such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are driving the market. According to the WORLD HEALTH ORGANIZATION (WHO), at least 2.2 Billion individuals each year have a near of distance vision impairment. The report also states that minimum 1 Billion of these cases of vision impairment could have been avoided or is yet to be prevented. The rising number of individuals with eye diseases are significantly leading to a rise in the demand for these therapeutic drugs such as anti-glaucoma medications, anti-VEGF agents, and anti-inflammatory agents. This correlation is supported by numerous market research reports which depict promising advanced treatment solutions and promote ophthalmic drugs market recent development activities.

Significant Technological Advancements in Drug Delivery Systems

The innovation of drug delivery systems, which can be accredited to novel technologies has been a major factor in creating a positive ophthalmic drugs market overview. New formulation possibilities such as microemulsions, nanotechnology, or ocular inserts offer better efficacy, safety, and patient adherence. For instance, drug carriers at a nano-size scale can significantly improve the bioavailability of the drug to the targeted ocular tissues, thereby reducing the need for frequent dosing and any side effects associated with the drug. As a result, more companies are investing in these technologies in order to gain a competitive edge in the market. There is a growing number of novel ophthalmic drug delivery system patents in the industry. All of the aforementioned research and development (R&D) investments are underpinned by the projections of market growth within the segments that benefit from new drug delivery technologies. This implies their ability to significantly disrupt the present ophthalmology treatment paradigm.

Favorable Government Initiatives and Funding

Government policies and act as a vital factor creating a positive ophthalmic drugs market outlook. Governments worldwide have launched various initiatives to improve healthcare infrastructure, including making effective eye care more accessible. For instance, numerous countries provide opportunities for subsidizing the opening and development of eye care centers, investing in research to create new drugs, and spreading information about eye diseases. In the United States, the National Eye Institute provides significant funding for research in the ophthalmic field. This propels a significant breakthrough in this area, opening up new drugs and opportunities in the industry for good vision. Moreover, faster drug approvals through routes such as FDA's Breakthrough Therapy designation improve market entry for visionary ophthalmic solutions.

Ophthalmic Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, drug class, indication, dosage form, and distribution channel.

Breakup by Type:

Prescription Drugs

Over-the-counter Drugs

Prescription drugs accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes prescription drugs and over-the-counter drugs. According to the report, prescription drugs represented the largest segment.

The highest ophthalmic drugs market revenue is deriving from prescription drugs. This can be accredited to the requirement of regulated forms of treatment for certain complex or severe eye disorders. Glaucoma, age-regulated macular degeneration, diabetic retinopathy, and many other conditions are typically treated with prescription medication that must be administered in precise dosages and only used through patient monitoring by a healthcare provider. Age-related macular degeneration can be categorized as dry AMD and wet AMD, and is a primary case of vision loss in individuals 50 years or older. Approximately 80% of individuals (8 out of 10) are diagnosed with dry form AMD. The rapid growth of the patient population proves the irreplaceability of prescription drugs in successful disease treatment and therapy.

Breakup by Drug Class:

Anti-glaucoma

Anti-infection

Anti-inflammation

Anti-allergy

Others

Anti-glaucoma holds the largest share in the industry

A detailed breakup and analysis of the market based on the drug class have also been provided in the report. This includes anti-glaucoma, anti-infection, anti-inflammation, anti-allergy, and others. According to the report, anti-glaucoma accounted for the largest market share.

The largest ophthalmic drugs market share is held by anti-glaucoma drugs, where glaucoma is the second leading cause of irreversible blindness globally. According to the NATIONAL INSTITUE OF HEALTH (NIH), the number of individuals suffering with glaucoma globally will rise upto 111.8 million by 2040. A rapidly growing glaucoma patient population signifies that patients need effective therapeutics on a long-term basis in order to maintain visual function, and hence there is significant demand for this segment. Additionally, drug formulation is constantly being developed to achieve maximum relief for glaucoma patients and compliance with the treatment on the part of the patient.

Breakup by Indication:

Dry Eye

Glaucoma

Infection/Inflammation/Allergy

Retinal Disorders

Others

Retinal disorders represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. According to the report, retinal disorders represented the largest segment.

Retinal disorders account for a large part of the ophthalmic drugs market, mainly due to the high frequency of diseases and their severity, which includes diabetic retinopathy and age-related macular degeneration. As per a report published by the NATIONAL INSTITUE OF HEALTH (NIH), individuals diagnosed with type 1, type 2, and gestational diabetes are more prone to diabetic retinopathy. The report also suggested that diabetic retinopathy can also lead to other serious eye conditions, such as diabetic macular edema and neovascular glaucoma. With time, approximately 1 in 15 individuals with diabetes develop DME. In the absence of treatment, these diseases often lead to complete blindness and require constant drug support, due to which the consumption of drugs in this segment is significant.

Breakup by Dosage Form:

Liquid Ophthalmic Drug Forms

Solid Ophthalmic Drug Forms

Semisolid Ophthalmic Drug Forms

Multicompartment Drug Delivery Systems

Others

Liquid ophthalmic drug forms exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the dosage form have also been provided in the report. This includes liquid ophthalmic drug forms, solid ophthalmic drug forms, semisolid ophthalmic drug forms, multicompartment drug delivery systems, and others. According to the report, liquid ophthalmic drug forms accounted for the largest market share.

On account of the need for easily administered and fast-acting medication directly into the eye, liquid ophthalmic drugs are the largest segment in the market by dosage form. Liquid dosage forms include drops, solutions, tinctures, injections, tinctures, elixirs, and syrups. Considering the relatively wide range of methods for delivering liquid medication into the eye, drops are the most prevalent, offering better controllability of dosage and higher patient adherence, thus impelling the ophthalmic drugs market growth. As per the NATIONAL INSTITUTE OF HEALTH (NIH), demand for liquid ophthalmic formulations is prominently high, with 90% of prescribed medications being eye drops. It is also driven by the introduction of non-preserved and multi-dose packaging, which increases convenience and safety. Thus, liquid formulations are widely preferred by patient and healthcare providers in cases of eye conditions.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores

Online Pharmacies

Others

Hospital pharmacies dominates the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, drug stores, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

In the market breakup by distribution channel, hospital pharmacies currently constitute the largest segment. The factor dictating this is the direct integration of these pharmacies into the healthcare facilities and immediate patient care. As a result, patients have timely access to the ophthalmic medications prescribed by their ophthalmologists. Early treatment of acute and chronic eye conditions is essential to prevent vision impairment and blindness. Hospital pharmacies, in turn, are the first to receive new drug approvals, given their affiliation with manufacturers and the purchasing power. As a result, the drug distribution and administration process are facilitated, patient adherence improves, and outcomes enhance.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest ophthalmic drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America holds the largest market share due to the developed healthcare system of the region, high healthcare expenditures, and strong presence of big pharma. Moreover, the eye disease rate in the North is high due to glaucoma, for instance, according to the NATIONAL HEALTH INSTITUE (NIH), 3 million individuals in the United States are affected by glaucoma. Another prominent reason is the sponsorship of the United States in medical research, with eye treatment gaining notable financial support.

Competitive Landscape:

The ophthalmic drugs market report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the metal fiber industry include AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Numerous major ophthalmic drugs companies are extensively involved in research and development (R&D) activities to develop new products and broaden their portfolios. For instance, in January 2023 BAUSCH HEALTH COMPANIES INC., announced the launch of PreserVision AREDS 2 Formula minigel eye vitamins in the United States. This drug acts as a therapeutic solution for individuals diagnosed with moderate-to-advanced AMD. Leading corporations such as Novartis, Roche, and Pfizer are currently working on new treatments for everything from glaucoma to age-related macular degeneration. They are also pioneering new drug delivery technologies to help medications work more effectively while still increasing patient compliance. Furthermore, these organizations have collaborated or acquired one another as part of their core business strategies, enabling them to take advantage of the other's technology capabilities and reach in different markets. The leading firms of the sector have also engaged in a large number of clinical reviews, contributing to the rapid introduction of new efficient goods.

Latest News:

February 2023: BAYER AG proposed aflibercept 8mg for regulatory approval in the EU for two major retinal illnesses.

March 2022: THEA PHARMA announced the acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. This strategic step supports the position of Thea as a major provider of products manufactured to cater to the demands of eye care specialists.

Key Questions Answered in This Report:

  • How has the global ophthalmic drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global ophthalmic drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global ophthalmic drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive ophthalmic drugs market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the ophthalmic drugs market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the ophthalmic drugs market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the ophthalmic drugs market?
  • What is the breakup of the market based on the dosage form?
  • Which is the most attractive dosage form in the ophthalmic drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the ophthalmic drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global ophthalmic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ophthalmic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Anti-glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anti-infection
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Anti-inflammation
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Dry Eye
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Glaucoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infection/Inflammation/Allergy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Retinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Dosage Form

  • 9.1 Liquid Ophthalmic Drug Forms
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Solid Ophthalmic Drug Forms
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Semisolid Ophthalmic Drug Forms
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Multicompartment Drug Delivery Systems
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Drug Stores
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Aerie Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Akorn Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Alcon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Bausch Health Companies Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Bayer AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Regeneron Pharmaceuticals Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Santen Pharmaceutical Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Sun Pharmaceutical Industries Ltd.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Ophthalmic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Ophthalmic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Ophthalmic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Ophthalmic Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Ophthalmic Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Ophthalmic Drugs Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: Ophthalmic Drugs Market: Breakup by Dosage Form (in %), 2023
  • Figure 8: Global: Ophthalmic Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 9: Global: Ophthalmic Drugs Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Ophthalmic Drugs (Prescription Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Ophthalmic Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Ophthalmic Drugs (Anti-glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Ophthalmic Drugs (Anti-glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Ophthalmic Drugs (Anti-infection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Ophthalmic Drugs (Anti-infection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Ophthalmic Drugs (Anti-inflammation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Ophthalmic Drugs (Anti-inflammation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Ophthalmic Drugs (Anti-allergy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Ophthalmic Drugs (Anti-allergy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Ophthalmic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Ophthalmic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Ophthalmic Drugs (Dry Eye) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Ophthalmic Drugs (Dry Eye) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Ophthalmic Drugs (Glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Ophthalmic Drugs (Glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Ophthalmic Drugs (Retinal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Ophthalmic Drugs (Retinal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Ophthalmic Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Ophthalmic Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Ophthalmic Drugs (Other Dosage Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Ophthalmic Drugs (Other Dosage Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Ophthalmic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Ophthalmic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Ophthalmic Drugs (Drug Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Ophthalmic Drugs (Drug Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Ophthalmic Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Ophthalmic Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Global: Ophthalmic Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Global: Ophthalmic Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: North America: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: North America: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United States: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United States: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Canada: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Canada: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Asia-Pacific: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Asia-Pacific: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: China: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: China: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Japan: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Japan: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: India: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: India: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: South Korea: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: South Korea: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Australia: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Australia: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Indonesia: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Indonesia: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Europe: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Europe: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Germany: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Germany: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: France: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: France: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: United Kingdom: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: United Kingdom: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Italy: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Italy: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Spain: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Spain: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Russia: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Russia: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Latin America: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Latin America: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Brazil: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Brazil: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Mexico: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Mexico: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Others: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Middle East and Africa: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 99: Middle East and Africa: Ophthalmic Drugs Market: Breakup by Country (in %), 2023
  • Figure 100: Middle East and Africa: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 101: Global: Ophthalmic Drugs Industry: SWOT Analysis
  • Figure 102: Global: Ophthalmic Drugs Industry: Value Chain Analysis
  • Figure 103: Global: Ophthalmic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ophthalmic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Ophthalmic Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Ophthalmic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Ophthalmic Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: Ophthalmic Drugs Market Forecast: Breakup by Dosage Form (in Million US$), 2024-2032
  • Table 6: Global: Ophthalmic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: Ophthalmic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Ophthalmic Drugs Market: Competitive Structure
  • Table 9: Global: Ophthalmic Drugs Market: Key Players